X4 Pharmaceuticals
One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States
Website: http://www.x4pharma.com/
112 articles with X4 Pharmaceuticals
-
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
4/11/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common stock. All of the securities in the offering will be sold by X4.
-
X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors
4/2/2019
Dr. Stewart currently serves as Chief Medical Officer of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity.
-
X4 Pharmaceuticals Provides Business and Clinical Development Update
4/1/2019
Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections and Myelokathexis syndrome in second quarter 2019 having finalized the protocol based on FDA guidance
-
X4 Pharmaceuticals Completes Merger with Arsanis
3/13/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the completion of its merger with Arsanis, Inc. (Nasdaq: ASNS, through March 13, 2019), effective as of March 13, 2019.
-
X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P-001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial
12/1/2018
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 allosteric antagonist drugs to improve immune cell trafficking to treat rare diseases and cancer, today announced the presentation of additional Phase 2 clinical data demonstrating a positive safety profile and clinical activity of X4P-001 in patients with WHIM syndrome, a rare primary immunodeficiency disease.
-
Shares of Arsanis, Inc. stock are up more than 25 percent in premarket trading after the company announced that it will merge with privately-held X4 Pharmaceuticals, Inc. as part of a reverse merger that will provide X4 with a quick path to being traded on the Nasdaq.
-
X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity through CXCR4 Antagonism
11/6/2018
X4 Pharmaceuticals, today highlighted data from a poster presentation of a clinical study with X4P-001-IO, an investigational CXCR4 allosteric antagonist, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, being held November 7-11, 2018, in Washington, D.C.
-
X4 Pharmaceuticals Appoints Gary J. Bridger, PhD, to Board of Directors
11/5/2018
Leader brings expertise in financing, corporate planning and R&D strategy for biotechnology companies
-
X4 Pharmaceuticals to Present Clinical Data Used to Determine Phase 3 Dose from Phase 2/3 Study of X4P-001-RD in WHIM Syndrome
11/1/2018
Study designed to evaluate X4P-001-RD in a rare genetic, primary immunodeficiency disease to be presented at the American Society of Hematology meeting
-
X4 Pharmaceuticals Presents Clinical Data Showing Combination of X4P-001 and Opdivo® (nivolumab) Improved Clinical Responses in RCC Patients Unresponsive to Opdivo Monotherapy
10/19/2018
Findings with combination therapy of anti-PD-1 and CXCR4 antagonist in patients with clear cell renal cell carcinoma (ccRCC) presented in Poster Discussion session at ESMO 2018
-
X4 Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for X4P-001-RD for the Treatment of WHIM Syndrome
10/15/2018
X4 Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s drug candidate, X4P-001-RD for the treatment of WHIM syndrome
-
X4 Pharmaceuticals and Collaborators Present Data that WHIM Syndrome is Underdiagnosed and Patients are Impacted by Broad Spectrum of Medical Complications
10/15/2018
Three poster presentations showcased at NORD Rare Disease Summit
-
X4 Pharmaceuticals to Present Clinical Data at Upcoming Oncology Medical Conferences
10/9/2018
Data to highlight X4P-001-IO, orally bioavailable CXCR4 antagonist, in advanced renal cell carcinoma and melanoma
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors
7/12/2018
Mr. Wyzga brings leadership experience, including in rare diseases and cancer
-
X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of X4P-001-RD in Patients with WHIM Syndrome
6/15/2018
Dose dependent increases in absolute neutrophil and lymphocyte counts observed in all patients treated with X4P-001-RD
-
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
-
X4 Pharmaceuticals Reports Positive Clinical Data from Phase 2 Expansion Study of X4P-001-IO and Axitinib in Patients with Clear Cell Renal Cell Carcinoma
6/2/2018
X4 Pharmaceuticals announced positive clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM Syndrome
5/17/2018
X4 Pharmaceuticals will present clinical data highlighting their Phase II X4P-001-RD drug.